Skip to main content
NIH funding notice RFA-MH-24-331

Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R21 Clinical Trial Optional)

Closed on November 22, 2023.

Posted
September 20, 2023
Close date
November 22, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $211,141 in first-year total cost, median $211,141.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 HSS-H (50)]1

Most frequent institutions

  1. EMORY UNIVERSITY1
Competing awards under RFA-MH-24-331 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Meeting South African adolescent girls and young women who experience intimate partner violence where they are: Developing an implementation strategy for linkage to PrEP options1R21MH137783-01BEKKER, LINDA-GAIL GAILGIOVENCO, DANIELLEEMORY UNIVERSITY, GA$211,141ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.